Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 22	FEB 05	German (DE) application and patent publication number format changes

NEWS EXPRESS	DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:26:40 ON 12 FEB 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:26:54 ON 12 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 FEB 2004 HIGHEST RN 649538-27-2
DICTIONARY FILE UPDATES: 11 FEB 2004 HIGHEST RN 649538-27-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\09839289.1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 13:27:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 348 TO ITERATE

100.0% PROCESSED 348 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L2 1 SEA SSS FUL L1

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'MARPAT' ENTERED AT 13:27:28 ON 12 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 06)(20040206 ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6673954 06 JAN 2004
DE 10317295 08 JAN 2004
EP 1380632 14 JAN 2004
JP 2004014584 15 JAN 2004
WO 2004004674 15 JAN 2004

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 13:27:36 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 1999 TO ITERATE

100.0% PROCESSED 1999 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.09

L3 8 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 109.42 265.05

FILE 'CAPLUS' ENTERED AT 13:27:51 ON 12 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Feb 2004 VOL 140 ISS 7
FILE LAST UPDATED: 11 Feb 2004 (20040211/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 8 L3

=> s l2
L5 7 L2

=> d his

(FILE 'HOME' ENTERED AT 13:26:40 ON 12 FEB 2004)

FILE 'REGISTRY' ENTERED AT 13:26:54 ON 12 FEB 2004
L1 STRUCTURE UPLOADED
L2 1 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 13:27:28 ON 12 FEB 2004
L3 8 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:27:51 ON 12 FEB 2004
L4 8 S L3
L5 7 S L2

=> d l5 fbib hitstr abs total

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:77551 CAPLUS
DN 138:131150
TI Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives
IN Glasky, Alvin J.; Fick, David B.; Helton, David
PA USA
SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U. S. Ser. No. 839,289.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003022892	A1	20030130	US 2002-193550	20020709
				US 2001-839289 A2	20010420
	US 2002198218	A1	20021226	US 2001-839289	20010420

PATENT FAMILY INFORMATION:

FAN 2002:832760

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085856	A1	20021031	WO 2002-US11142	20020408
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-839289 A	20010420
	US 2002198218	A1	20021226	US 2001-839289	20010420
	EP 1383742	A1	20040128	EP 2002-725584	20020408
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-839289 A	20010420
				WO 2002-US11142W	20020408

FAN 2003:117681

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011396	A1	20030213	WO 2002-US24260	20020730
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-308644PP	20010730
				US 2002-365005PP	20020313
				US 2002-371381PP	20020409

FAN 2003:473263

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	US 2003114463	A1	20030619	US 2002-209451	20020730
				US 2001-839289 A2	20010420
				US 2001-308644PP	20010730
				US 2002-365005PP	20020313
				US 2002-371381PP	20020409
	US 2002198218	A1	20021226	US 2001-839289	20010420

OS MARPAT 138:131150

IT **389799-42-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(and metabolites; treating cognitive/attention deficit disorders using tetrahydroindolone analogs and derivs.)

RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB Methods for treating cognitive/attention deficit disorders in general using tetrahydroindolone derivs. and analogs, particularly tetrahydroindolone derivs. or analogs in which the tetrahydroindolone derivative or analog is covalently linked to another moiety to form a bifunctional conjugate are disclosed. More specifically, methods and compns. for treating attention deficit disorder and attention deficit hyperactivity disorders in adults and children as well as mild cognitive impairment and dementia are provided.

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:832760 CAPLUS

DN 137:337779

TI Preparation of tetrahydroindolone analogs and derivatives as nootropic agents

IN Fick, David B.; Foreman, Mark M.; Glasky, Alvin J.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085856	A1	20021031	WO 2002-US11142	20020408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-839289 A 20010420

US 2002198218 A1 20021226 US 2001-839289 20010420
EP 1383742 A1 20040128 EP 2002-725584 20020408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2001-839289 A 20010420
WO 2002-US11142W 20020408

PATENT FAMILY INFORMATION:

FAN 2003:77551

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003022892	A1	20030130	US 2002-193550	20020709
				US 2001-839289 A2	20010420
	US 2002198218	A1	20021226	US 2001-839289	20010420

FAN 2003:117681

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011396	A1	20030213	WO 2002-US24260	20020730

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-308644PP 20010730
US 2002-365005PP 20020313
US 2002-371381PP 20020409

FAN 2003:473263

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003114463	A1	20030619	US 2002-209451	20020730
				US 2001-839289 A2	20010420
				US 2001-308644PP	20010730
				US 2002-365005PP	20020313
				US 2002-371381PP	20020409
	US 2002198218	A1	20021226	US 2001-839289	20010420

OS MARPAT 137:337779

IT **389799-42-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydroindolone analogs and derivs. as nootropic agents)

RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



GI



I

AB Tetrahydroindolone analogs and derivs. (e.g., I; wherein R = H, Et) were prepared Compound I (R = Et) was prepared in 56% yield by reacting acryloyl chloride with 4-aminobenzoic acid Et ester to give 76% 4-acryloylaminobenzoic acid Et ester, followed by reaction with 1,5,6,7-tetrahydro-4H-indol-4-one. Compound I (R = H) is then accessed through hydrolysis of the product. The prepared compds. showed good activity as nootropic agents. Thus, the minimal ED of I (R = Et) was 0.001 mg/kg in a passive avoidance test on mice.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:51464 CAPLUS
DN 136:112673
TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for treatment of disease-induced peripheral neuropathy and related conditions
IN Diamond, Jack; Glasky, Alvin J.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004452	A2	20020117	WO 2001-US21526	20010706
	WO 2002004452	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,

YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2000-216844PP 20000707
US 2002055506 A1 20020509 US 2001-900844 20010706
US 6630490 B2 20031007
US 2000-216844PP 20000707
US 2002061899 A1 20020523 US 2001-899901 20010706
US 6630478 B2 20031007
US 2000-216844PP 20000707
EP 1334103 A2 20030813 EP 2001-950964 20010706
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2000-216844PP 20000707
WO 2001-US21526W 20010706

PATENT FAMILY INFORMATION:

FAN 2002:51460

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004448	A2	20020117	WO 2001-US21373	20010706
	WO 2002004448	A3	20030123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2000-216844PP 20000707
US 2002055506 A1 20020509 US 2001-900844 20010706
US 6630490 B2 20031007
US 2000-216844PP 20000707
US 2002061899 A1 20020523 US 2001-899901 20010706
US 6630478 B2 20031007
US 2000-216844PP 20000707
EP 1334104 A2 20030813 EP 2001-952464 20010706
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2000-216844PP 20000707
WO 2001-US21373W 20010706

OS MARPAT 136:112673

IT **389799-42-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine derivs., pyrimidine derivs., and tetrahydroindolone derivs. for treatment of disease-induced peripheral neuropathy and related conditions)

RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine derivative or analog, a tetrahydroindolone derivative or analog, or a pyrimidine derivative or analog. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The disease-induced peripheral neuropathy can be diabetic neuropathy or disease-induced peripheral neuropathy with another basis.

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:51463 CAPLUS
DN 136:112672
TI Methods using a purine derivative,pyrimidine derivative, or tetrahydroindolone derivative for stimulation of synthesis of synaptophysin in the central nervous system
IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004451	A2	20020117	WO 2001-US21385	20010706
	WO 2002004451	A3	20030103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-216808PP	20000707
	US 2002040032	A1	20020404	US 2001-899478	20010705
				US 2000-216808PP	20000707

OS MARPAT 136:112672
IT **389799-42-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine derivative,pyrimidine derivative, or tetrahydroindolone derivative for stimulation of synthesis of synaptophysin in CNS)
RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB A method of increasing the synthesis and/or secretion of synaptphysin comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine derivative of analog, a tetrahydroindolone derivative or analog, or a pyrimidine derivative or analog. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compound can pass through the blood-brain barrier. A particularly preferred purine derivative is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:51462 CAPLUS
DN 136:112671
TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for prevention of accumulation of amyloid β peptide in the central nervous system
IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004450	A2	20020117	WO 2001-US21384	20010706
	WO 2002004450	A3	20021212		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-216845PP	20000707
	US 2002040031	A1	20020404	US 2001-899611	20010705
				US 2000-216845PP	20000707

OS MARPAT 136:112671
IT **389799-42-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for
prevention of accumulation of amyloid β peptide in CNS)
RN 389799-42-2 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB A method of either inhibiting the formation of Aβ or stimulating the formation of sAPP comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine derivative or analog, a tetrahydroindolone derivative or analog, or a pyrimidine derivative or analog. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compound can pass through the blood-brain barrier. A particularly preferred purine derivative is N-4- carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:51461 CAPLUS
DN 136:112691
TI Methods using a purine derivative, a pyrimidine derivative or a tetrahydroindolone derivative for treatment of conditions affected by activity of multidrug transporters
IN Taylor, Eve M.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004449	A2	20020117	WO 2001-US21383	20010706
	WO 2002004449	A3	20020613		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-216616PP	20000707
	US 2002128264	A1	20020912	US 2001-900297	20010706
				US 2000-216616PP	20000707

OS MARPAT 136:112691
IT **389799-42-2**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine derivative, pyrimidine derivative or tetrahydroindolone derivative for
treatment of conditions affected by activity of multidrug transporters)
RN 389799-42-2 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB One aspect of the invention is a method of treating a condition or disease associated with the activity of a multidrug transporter protein comprising administering to a mammal with a condition or disease associated with the activity of a multidrug transporter protein an effective quantity of a purine derivative or analog, a tetrahydroindolone derivative or analog, or a pyrimidine derivative or analog. If the compound is a purine derivative, the purine
moiety can be guanine or hypoxanthine. A particularly preferred bifunctional purine derivative is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide. The methods of the invention can be used to treat cancer, a microbial or parasitic infection, HIV, infection, or a condition associated with inflammation, e.g. asthma or rheumatic disease.

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:51460 CAPLUS
DN 136:112670
TI Methods using purine derivatives, pyrimidine derivatives, and tetrahydroindolone derivatives for treatment of drug-induced peripheral neuropathy and related conditions
IN Diamond, Jack; Glasky, Alvin J.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004448	A2	20020117	WO 2001-US21373	20010706
	WO 2002004448	A3	20030123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2000-216844PP 20000707

	US 2002055506	A1	20020509	US 2001-900844	20010706
	US 6630490	B2	20031007		
				US 2000-216844PP	20000707
	US 2002061899	A1	20020523	US 2001-899901	20010706
	US 6630478	B2	20031007		
				US 2000-216844PP	20000707
	EP 1334104	A2	20030813	EP 2001-952464	20010706
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-216844PP	20000707
				WO 2001-US21373W	20010706

PATENT FAMILY INFORMATION:

FAN 2002:51464

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004452	A2	20020117	WO 2001-US21526	20010706
	WO 2002004452	A3	20030103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-216844PP	20000707
	US 2002055506	A1	20020509	US 2001-900844	20010706
	US 6630490	B2	20031007		
				US 2000-216844PP	20000707
	US 2002061899	A1	20020523	US 2001-899901	20010706
	US 6630478	B2	20031007		
				US 2000-216844PP	20000707
	EP 1334103	A2	20030813	EP 2001-950964	20010706
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-216844PP	20000707
				WO 2001-US21526W	20010706

OS MARPAT 136:112670

IT **389799-42-2**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(purine derivs., pyrimidine derivs., and tetrahydroindolone derivs. for treatment of drug-induced peripheral neuropathy and related conditions)

RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB A method of treating drug-induced peripheral neuropathy comprises

administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analog, a tetrahydroindolone derivative or analog, or a pyrimidine derivative or analog. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy associated with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. The methods of the invention are particularly useful in treating peripheral neuropathy associated with the administration of vincristine, paclitaxel, or cisplatin.

=> d his

(FILE 'HOME' ENTERED AT 13:26:40 ON 12 FEB 2004)

FILE 'REGISTRY' ENTERED AT 13:26:54 ON 12 FEB 2004
L1 STRUCTURE UPLOADED
L2 1 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 13:27:28 ON 12 FEB 2004
L3 8 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:27:51 ON 12 FEB 2004
L4 8 S L3
L5 7 S L2

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:77551 CAPLUS
DN **138:131150**
TI Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives
IN Glasky, Alvin J.; Fick, David B.; Helton, David
PA USA
SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U. S. Ser. No. 839,289.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003022892	A1	20030130	US 2002-193550	20020709
				US 2001-839289 A2	20010420
	US 2002198218	A1	20021226	US 2001-839289	20010420

PATENT FAMILY INFORMATION:
FAN 2002:832760

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085856	A1	20021031	WO 2002-US11142	20020408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-839289 A 20010420

US 2002198218	A1	20021226	US 2001-839289	20010420
EP 1383742	A1	20040128	EP 2002-725584	20020408

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2001-839289 A 20010420
WO 2002-US11142W 20020408

FAN 2003:117681

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003011396	A1	20030213	WO 2002-US24260	20020730

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-308644PP 20010730
US 2002-365005PP 20020313
US 2002-371381PP 20020409

FAN 2003:473263

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003114463	A1	20030619	US 2002-209451	20020730
			US 2001-839289 A2	20010420
			US 2001-308644PP	20010730
			US 2002-365005PP	20020313
			US 2002-371381PP	20020409
US 2002198218	A1	20021226	US 2001-839289	20010420

OS MARPAT 138:131150

AB Methods for treating cognitive/attention deficit disorders in general using tetrahydroindolone derivs. and analogs, particularly tetrahydroindolone derivs. or analogs in which the tetrahydroindolone derivative or analog is covalently linked to another moiety to form a bifunctional conjugate are disclosed. More specifically, methods and compns. for treating attention deficit disorder and attention deficit hyperactivity disorders in adults and children as well as mild cognitive impairment and dementia are provided.

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:832760 CAPLUS
DN **137:337779**
TI Preparation of tetrahydroindolone analogs and derivatives as nootropic agents

IN Fick, David B.; Foreman, Mark M.; Glasky, Alvin J.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085856	A1	20021031	WO 2002-US11142	20020408
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-839289 A	20010420
	US 2002198218	A1	20021226	US 2001-839289	20010420
	EP 1383742	A1	20040128	EP 2002-725584	20020408
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-839289 A	20010420
				WO 2002-US11142W	20020408

PATENT FAMILY INFORMATION:

FAN 2003:77551

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003022892	A1	20030130	US 2002-193550	20020709
				US 2001-839289 A2	20010420
	US 2002198218	A1	20021226	US 2001-839289	20010420

FAN 2003:117681

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011396	A1	20030213	WO 2002-US24260	20020730
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-308644PP	20010730
				US 2002-365005PP	20020313
				US 2002-371381PP	20020409

FAN 2003:473263

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003114463	A1	20030619	US 2002-209451	20020730
				US 2001-839289 A2	20010420
				US 2001-308644PP	20010730

US 2002-365005PP 20020313
US 2002-371381PP 20020409
US 2002198218 A1 20021226 US 2001-839289 20010420
OS MARPAT 137:337779
GI



I

AB Tetrahydroindolone analogs and derivs. (e.g., I; wherein R = H, Et) were prepared Compound I (R = Et) was prepared in 56% yield by reacting acryloyl chloride with 4-aminobenzoic acid Et ester to give 76% 4-acryloylaminobenzoic acid Et ester, followed by reaction with 1,5,6,7-tetrahydro-4H-indol-4-one. Compound I (R = H) is then accessed through hydrolysis of the product. The prepared compds. showed good activity as nootropic agents. Thus, the minimal ED of I (R = Et) was 0.001 mg/kg in a passive avoidance test on mice.
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:522636 CAPLUS
DN **137:73275**
TI Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
IN Taylor, Eve M.
PA USA
SO U.S. Pat. Appl. Publ., 28 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002091133	A1	20020711	US 2001-22032	20011212
			US 2000-254910PP	20001212
WO 2002058736	A2	20020801	WO 2001-US48595	20011212
WO 2002058736	A3	20030807		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,

TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2000-254910PP 20001212

OS MARPAT 137:73275

AB The invention provides a method of inducing neurogenesis by administering to a mammal an effective quantity of a compound that induces neurogenesis, where neurogenesis includes proliferation of neural stem and progenitor cells, differentiation of these cells into neurons, and/or survival of these new neurons. In general, the compound comprises three moieties, A, L, and B, covalently linked. A can be a purine, tetrahydroindolone, or pyrimidine; L is a linker, while B is a moiety that promotes absorption of the compound A particularly preferred compound is N-4-[[3-(6-oxo-1,6-dihydropurin-9-yl)-1-oxopropyl]amino]benzoic acid (also known as AIT-082 or leteprinim potassium). Another aspect of the invention is pharmaceutical compns. for inducing neurogenesis.

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:51464 CAPLUS
DN **136:112673**
TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for treatment of disease-induced peripheral neuropathy and related conditions
IN Diamond, Jack; Glasky, Alvin J.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004452	A2	20020117	WO 2001-US21526	20010706
	WO 2002004452	A3	20030103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-216844PP	20000707
	US 2002055506	A1	20020509	US 2001-900844	20010706
	US 6630490	B2	20031007		
				US 2000-216844PP	20000707
	US 2002061899	A1	20020523	US 2001-899901	20010706
	US 6630478	B2	20031007		
				US 2000-216844PP	20000707
	EP 1334103	A2	20030813	EP 2001-950964	20010706
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-216844PP	20000707
				WO 2001-US21526W	20010706

PATENT FAMILY INFORMATION:
FAN 2002:51460

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004448	A2	20020117	WO 2001-US21373	20010706
	WO 2002004448	A3	20030123		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-216844PP	20000707
	US 2002055506	A1	20020509	US 2001-900844	20010706
	US 6630490	B2	20031007		
				US 2000-216844PP	20000707
	US 2002061899	A1	20020523	US 2001-899901	20010706
	US 6630478	B2	20031007		
				US 2000-216844PP	20000707
	EP 1334104	A2	20030813	EP 2001-952464	20010706
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-216844PP	20000707
				WO 2001-US21373W	20010706

OS MARPAT 136:112673

AB A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine derivative or analog, a tetrahydroindolone derivative or analog, or a pyrimidine derivative or analog. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The disease-induced peripheral neuropathy can be diabetic neuropathy or disease-induced peripheral neuropathy with another basis.

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:51463 CAPLUS

DN **136:112672**

TI Methods using a purine derivative,pyrimidine derivative, or tetrahydroindolone derivative for stimulation of synthesis of synaptophysin in the central nervous system

IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004451	A2	20020117	WO 2001-US21385	20010706
	WO 2002004451	A3	20030103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2000-216808PP 20000707
US 2002040032 A1 20020404 US 2001-899478 20010705
US 2000-216808PP 20000707

OS MARPAT 136:112672

AB A method of increasing the synthesis and/or secretion of synaptphysin comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine derivative of analog, a tetrahydroindolone derivative or analog, or a pyrimidine derivative or analog. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compound can pass through the blood-brain barrier. A particularly preferred purine derivative is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:51462 CAPLUS

DN **136:112671**

TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for prevention of accumulation of amyloid β peptide in the central nervous system

IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002004450	A2	20020117	WO 2001-US21384	20010706
WO 2002004450	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2000-216845PP 20000707
US 2002040031 A1 20020404 US 2001-899611 20010705
US 2000-216845PP 20000707

OS MARPAT 136:112671

AB A method of either inhibiting the formation of Aβ or stimulating the formation of sAPP comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine derivative or analog, a tetrahydroindolone derivative or

analog, or a pyrimidine derivative or analog. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compound can pass through the blood-brain barrier. A particularly preferred purine derivative is N-4- carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:51461 CAPLUS
DN **136:112691**
TI Methods using a purine derivative, a pyrimidine derivative or a tetrahydroindolone derivative for treatment of conditions affected by activity of multidrug transporters
IN Taylor, Eve M.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002004449	A2	20020117	WO 2001-US21383	20010706
WO 2002004449	A3	20020613		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			US 2000-216616PP	20000707
US 2002128264	A1	20020912	US 2001-900297	20010706
			US 2000-216616PP	20000707

OS MARPAT 136:112691
AB One aspect of the invention is a method of treating a condition or disease associated with the activity of a multidrug transporter protein comprising administering to a mammal with a condition or disease associated with the activity of a multidrug transporter protein an effective quantity of a purine derivative or analog, a tetrahydroindolone derivative or analog, or a pyrimidine derivative or analog. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. A particularly preferred bifunctional purine derivative is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide. The methods of the invention can be used to treat cancer, a microbial or parasitic infection, HIV, infection, or a condition associated with inflammation, e.g. asthma or rheumatic disease.

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:51460 CAPLUS
DN **136:112670**
TI Methods using purine derivatives, pyrimidine derivatives, and tetrahydroindolone derivatives for treatment of drug-induced peripheral neuropathy and related conditions
IN Diamond, Jack; Glasky, Alvin J.
PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004448	A2	20020117	WO 2001-US21373	20010706
	WO 2002004448	A3	20030123		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-216844PP	20000707
	US 2002055506	A1	20020509	US 2001-900844	20010706
	US 6630490	B2	20031007		
				US 2000-216844PP	20000707
	US 2002061899	A1	20020523	US 2001-899901	20010706
	US 6630478	B2	20031007		
				US 2000-216844PP	20000707
	EP 1334104	A2	20030813	EP 2001-952464	20010706
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-216844PP	20000707
				WO 2001-US21373W	20010706

PATENT FAMILY INFORMATION:
FAN 2002:51464

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004452	A2	20020117	WO 2001-US21526	20010706
	WO 2002004452	A3	20030103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-216844PP	20000707
	US 2002055506	A1	20020509	US 2001-900844	20010706
	US 6630490	B2	20031007		
				US 2000-216844PP	20000707
	US 2002061899	A1	20020523	US 2001-899901	20010706
	US 6630478	B2	20031007		
				US 2000-216844PP	20000707
	EP 1334103	A2	20030813	EP 2001-950964	20010706
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-216844PP	20000707
				WO 2001-US21526W	20010706

OS MARPAT 136:112670

AB A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analog, a tetrahydroindolone derivative or analog, or a pyrimidine derivative or analog. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy associated with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. The methods of the invention are particularly useful in treating peripheral neuropathy associated with the administration of vincristine, paclitaxel, or cisplatin.

```
=> d his

     (FILE 'HOME' ENTERED AT 13:26:40 ON 12 FEB 2004)

     FILE 'REGISTRY' ENTERED AT 13:26:54 ON 12 FEB 2004
L1              STRUCTURE UPLOADED
L2            1 S L1 SSS FULL

     FILE 'MARPAT' ENTERED AT 13:27:28 ON 12 FEB 2004
L3            8 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:27:51 ON 12 FEB 2004
L4            8 S L3
L5            7 S L2

=> s l4 and l5
L6            7 L4 AND L5

=> s neurogenesis and l6
L7            0 NEUROGENESIS AND L6

=> s neurogenesis and indole
L8            0 NEUROGENESIS AND INDOLE

=> s neurogenesis and indolone
L9            0 NEUROGENESIS AND INDOLONE

=> s neurogenesis and tetrahydroindolon
L10           0 NEUROGENESIS AND TETRAHYDROINDOLON

=> s neurogenesis and aminobenzoic acid and ester
L11           1 NEUROGENESIS AND AMINOBENZOIC ACID AND ESTER

=> d l11 fbib hitstr abs total

L11  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:814890  CAPLUS
DN   137:310756
TI   Synthesis of purine analogues and derivatives as nootropic agents
```

IN Fick, David B.; Foreman, Mark M.; Glasky, Alvin J.
PA USA
SO U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002156277	A1	20021024	US 2001-839290	20010420
WO 2002085904	A1	20021031	WO 2002-US11151	20020408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2001-839290 A 20010420

OS MARPAT 137:310756
GI



AB A purine derivative or analog comprising a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid **ester**, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacol. effects, promotes absorption or blood-brain barrier penetration of the derivative or analog, e.g. of formula I [R1 = H, alkyl, aralkyl, cycloalkyl, heteroalkyl; R2 = H, alkyl, cycloalkyl, halo, amino, etc.; L = hydrocarbyl, etc.; B = (substituted) OH, etc.] are prepared as nootropic agents. Thus, II was prepared from 4-[3-(6-oxo-1,6-dihydropurin-9-yl)propionylamino]benzoic acid Et **ester** and benzyl bromide in 82% yield. The minimal ED of II was 0.0003 mg/kg in a passive avoidance test on mice.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	130.05	395.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.09	-11.09

STN INTERNATIONAL LOGOFF AT 13:32:22 ON 12 FEB 2004